Envafolimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Unresectable or metastatic MSI-H or dMMR advanced solid tumors in adults (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Weak signal

Also in development:HIV · Phase 2 · investigational in the USChronic Hepatitis B · Phase 2 · investigational in the USEndometrial Cancer · Phase 2 · investigational in the US

Also approved (1)
CN
  • Unresectable or metastatic MSI-H or dMMR advanced solid tumors in adults
Product first approved 2021en.simcere.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05752136 · Sir Run Run Shaw Hospital
2023-04-01 – 2028-12 · Rectal Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06959693 · Sun Yat-sen University
2025-06-01 – 2030-06-30 · Metastatic Colorectal Cancer (CRC)
What this study did
Phase 2 (71)
Chronic Hepatitis B
Endometrial Cancer
NCT05112991 · 3D Medicines (Sichuan) Co., Ltd.
2022-03-04 – 2026-12 · Advanced Endometrial Cancer
What this study did
HIV
NCT05129189 · Shanghai Public Health Clinical Center
2022-06-29 – 2023-07-31 · HIV Infections
What this study did
Non-Small Cell Lung Cancer
NCT07818304 · The First People's Hospital of Lianyungang
2026-10 – 2028-10 · Non Small Cell Lung Cancer, Lung Neoplasms
What this study did
NCT06734182 · Guangdong Provincial People's Hospital
2024-06-22 – 2028-06-22 · Non-small Cell Lung Cancer
What this study did
NCT06618391 · Henan Cancer Hospital
2024-10-08 – 2026-10-30 · Non-small Cell Lung Cancer
What this study did
NCT05910034 · Fudan University
2023-07-01 – 2026-06-30 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT06108726 · Northern Jiangsu People's Hospital
2023-10-18 – 2025-10-18 · NSCLC
What this study did
NCT05055167 · The First Affiliated Hospital of Xiamen University
2021-08-30 – 2025-06-30 · Non-small Cell Lung Cancer Stage IV
What this study did
NCT05465733 · First Affiliated Hospital Xi'an Jiaotong University
2022-08-01 – 2025-06-30 · Non-Small-Cell Lung
What this study did
NCT05534113 · The First Affiliated Hospital with Nanjing Medical University
2022-12-01 – 2025-06-01 · Non-small Cell Lung Cancer
What this study did
NCT05414630 · Anhui Provincial Cancer Hospital
2022-06 – 2025-06 · Non-small Cell Lung Cancer Stage III
What this study did
NCT05360979 · Second Xiangya Hospital of Central South University
2022-05-15 – 2025-05-15 · Non-small Cell Lung Cancer
What this study did
NCT05243355 · Qilu Hospital of Shandong University
2021-12-03 – 2024-12-03 · Squamous Non-small Cell Lung Cancer
What this study did
NCT05203276 · The First People's Hospital of Lianyungang
2022-03-01 – 2024-06-30 · Lung Neoplasms
What this study did
NCT05529355 · Anhui Chest Hospital
2022-09-18 – 2023-09-18 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT07599995 · Sir Run Run Shaw Hospital
2026-05-30 – 2030-03-30 · Biliary Tract Cancer
What this study did
NCT06692491 · Peking University Shenzhen Hospital
2025-01-01 – 2029-12-31 · Rare Tumour
What this study did
NCT04910386 · 3D Medicines (Sichuan) Co., Ltd.
2027-06-01 – 2029-12 · Biliary Tract Neoplasms
What this study did
NCT06698965 · Shanghai Chest Hospital
2024-10-13 – 2029-10-31 · Lung Cancer, Small Cell
What this study did
NCT05959356 · Sun Yat-sen University
2023-11-09 – 2028-12-31 · Metastatic Colorectal Cancer
What this study did
NCT06772233 · Peking University
2025-07-30 – 2028-07-30 · Metastatic Gastrointestinal Stromal Tumors (GIST)
What this study did
NCT07729033 · Tianjin Medical University Cancer Institute and Hospital
2026-08 – 2028-07 · Advanced Biliary Tract Cancers
What this study did
NCT06055816 · Zhejiang Cancer Hospital
2023-10-24 – 2028-06-30 · Nasopharyngeal Carcinoma
What this study did
NCT07003815 · Tongji Hospital
2025-06 – 2028-06 · Biliary Tract Cancer, Advanced Cancer
What this study did
NCT07256223 · Fudan University
2026-12-01 – 2028-05-30 · Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis
What this study did
NCT04891198 · 3D Medicines (Sichuan) Co., Ltd.
2021-08-06 – 2028-04-30 · Solid Tumor
What this study did
NCT05799469 · Chongqing University Cancer Hospital
2023-05-01 – 2027-12-31 · Locally Advanced Cervical Cancer
What this study did
NCT05969847 · 池畔
2023-08-15 – 2027-12-31 · Rectal Cancer
What this study did
NCT07159191 · Peking Union Medical College Hospital
2025-09-01 – 2027-07-20 · Advanced Renal Cell Carcinoma (aRCC)
What this study did
NCT05904015 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-08-01 – 2027-06-30 · Lung Neoplasms
What this study did
NCT07243626 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-09-30 – 2027-06-01 · Soft Tissue Sarcoma
What this study did
NCT07559864 · Jian Li
2025-07-14 – 2027-06-01 · GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation
What this study did
NCT06498622 · Anhui Provincial Hospital
2024-07-20 – 2027-05-20 · Hepatocellular Carcinoma
What this study did
NCT06791083 · First Affiliated Hospital of Fujian Medical University
2024-06-20 – 2027-05 · Gastric Cancer
What this study did
NCT05722977 · Peking Union Medical College Hospital
2023-02-02 – 2027-02-02 · Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
What this study did
NCT06059261 · Chongqing University Cancer Hospital
2026-02-09 – 2027-02-01 · Nasopharyngeal Carcinoma
What this study did
NCT05397769 · Sun Yat-sen University
2022-06-08 – 2026-12-31 · Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
What this study did
NCT06321081 · Beijing Hospital
2024-03-01 – 2026-12-30 · RAS Mutation, Metastatic Colorectal Cancer, MSS
What this study did
NCT05941325 · Shanghai 6th People's Hospital
2023-04-01 – 2026-12-01 · Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
What this study did
NCT07142863 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2025-08-25 – 2026-09-30 · Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody, Envafolimab
What this study did
NCT06656559 · Tianjin Medical University Cancer Institute and Hospital
2024-10 – 2026-08 · Unresectable Biliary Tract Carcinoma
What this study did
NCT06014372 · Sun Yat-sen University
2023-07-01 – 2026-07-01 · Colon Cancer, Neoadjuvant Therapy, Immunotherapy
What this study did
NCT05685550 · Tianjin Medical University Cancer Institute and Hospital
2023-04-12 – 2026-05-31 · Progression Free Survival(PFS)
What this study did
NCT06041724 · Fudan University
2023-09-18 – 2026-03-18 · Advanced Mucosal Melanoma
What this study did
NCT06301828 · Nanjing First Hospital, Nanjing Medical University
2024-02-21 – 2026-02-21 · Gastrointestinal Neoplasms
What this study did
NCT06218004 · Hairong Liu
2024-01-25 – 2025-12-31 · Efficacy and Safety
What this study did
Phase 1/2 (4)
Non-Small Cell Lung Cancer
NCT05024214 · 3D Medicines (Sichuan) Co., Ltd.
2021-11-15 – 2026-12 · Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT07636798 · West China Hospital
2026-06 – 2029-12 · Biliary Tract Cancer
What this study did
NCT06663007 · Tianjin Medical University Second Hospital
2024-09-24 – 2027-08-31 · Prostate Cancer, CDK12 Gene Mutation
What this study did
NCT05448820 · Tracon Pharmaceuticals Inc.
2022-11-14 – 2025-09 · Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
What this study did
Phase 1 (2)
Other / comorbidity
NCT07260305 · Kangabio AUSTRALIA LTD PTY
2024-11-27 – 2027-03-30 · Advanced or Metastatic Solid Tumors
What this study did
NCT05849311 · 3D Medicines (Sichuan) Co., Ltd.
2023-05-29 – 2023-11-20 · Healthy Male
What this study did
Phase 4 (1)
Chronic Hepatitis B
NCT07573943 · The Second Affiliated Hospital of Chongqing Medical University
2024-05-21 – 2026-12-31 · Chronic Hepatitis b
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT07738055 · Tianjin Medical University Cancer Institute and Hospital
2026-07-31 – 2029-07-31 · Potentially Resectable Hepatocellular Carcinoma
What this study did
NCT05755009 · Jiangxi Provincial Cancer Hospital
2023-03-01 – 2025-02-20 · Metastatic Cancer
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Other / comorbidity

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for Chronic Hepatitis B: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Envafolimab: this drugPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Avelumab
Approved(overall)
Monoclonal antibodyPD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
IBC-Ab002
Phase 1(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

(31 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Envafolimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
December 2026 (9)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05024214 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Advanced CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07003815 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2026-12 · NCT05112991 · CT.gov ↗
What to watch
Phase 2Lung NeoplasmsNot yet recruiting
Est. primary completion 2026-12-30 · NCT05904015 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2026-12-30 · NCT07243626 · CT.gov ↗
What to watch
Phase 2RAS Mutation, Metastatic Colorectal Cancer, MSSRecruiting
Est. primary completion 2026-12-30 · NCT06321081 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT05959356 · CT.gov ↗
What to watch
Phase 2Chronic Hepatitis BRecruiting
Est. primary completion 2026-12-31 · NCT07852091 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2026-12-31 · NCT07573943 · CT.gov ↗
What to watch
2027 (15)
January 2027 (1)
Phase 1Advanced or Metastatic Solid TumorsRecruiting
Est. primary completion 2027-01-01 · NCT07260305 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-02-01 · NCT06059261 · CT.gov ↗
What to watch
Phase 2Advanced Renal Cell Carcinoma (aRCC)Not yet recruiting
Est. primary completion 2027-02-20 · NCT07159191 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-20 · NCT06498622 · CT.gov ↗
What to watch
Phase 1/2Prostate Cancer, CDK12 Gene MutationRecruiting
Est. primary completion 2027-05-31 · NCT06663007 · CT.gov ↗
What to watch
Phase 2Locally Advanced Cervical CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT05799469 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2GIST - Gastrointestinal Stromal Tumor, KIT Gene MutationRecruiting
Est. primary completion 2027-06-01 · NCT07559864 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-22 · NCT06734182 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Metastatic Gastrointestinal Stromal Tumors (GIST)Not yet recruiting
Est. primary completion 2027-07-30 · NCT06772233 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Solid TumorRecruiting
Est. primary completion 2027-08-30 · NCT04891198 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Clear Cell Renal Cell Cancer (ccRCC), Liver MetastasisNot yet recruiting
Est. primary completion 2027-11-01 · NCT07256223 · CT.gov ↗
What to watch
December 2027 (4)
Phase 2Advanced Biliary Tract CancersNot yet recruiting
Est. primary completion 2027-12 · NCT07729033 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT06123754 · CT.gov ↗
What to watch
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT05969847 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07599995 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07818304 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2/3Metastatic Colorectal Cancer (CRC)Not yet recruiting
Est. primary completion 2028-09-30 · NCT06959693 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Early phase / not applicablePotentially Resectable Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-01-31 · NCT07738055 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2Biliary Tract CancerRecruiting
Est. primary completion 2029-03 · NCT07636798 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Biliary Tract NeoplasmsNot yet recruiting
Est. primary completion 2029-06 · NCT04910386 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Lung Cancer, Small CellRecruiting
Est. primary completion 2029-10-31 · NCT06698965 · CT.gov ↗
What to watch

See the full readout calendar ↗